| Date Filed | Type | Description |
| 12/07/2020 |
GN
| Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead's Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology |
| 09/14/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout |
| 09/01/2020 |
GN
| Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program |
| 12/11/2019 |
GN
| Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma |
| 05/31/2019 |
GN
| Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| 12/10/2018 |
GN
| New Research Coverage Highlights Skyworks Solutions, Virtus Investment Partners, Altria Group, Gilead Sciences, Arthur J. Gallagher, and BP p.l.c — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 05/01/2018 |
BW
| Gilead Sciences Announces First Quarter 2018 Financial Results |
| 04/17/2018 |
BW
| Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018 |
| 04/17/2018 |
GN
| New Research Coverage Highlights DexCom, Equinix, Fitbit, Gilead Sciences, Humana, and Microsoft — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 02/06/2018 |
BW
| Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results |
| 02/01/2018 |
GN
| Market Trends Toward New Normal in Alexander's, Atrion, FS, Gilead Sciences, Abbott Laboratories, and Johnson & Johnson — Emerging Consolidated Expectations, Analyst Ratings |
| 01/23/2018 |
BW
| Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018 |
| 12/21/2017 |
BW
| Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8 |
| 12/07/2017 |
GN
| Gilead Sciences to Acquire Cell Design Labs |
| 11/28/2017 |
GN
| Analysis: Positioning to Benefit within Garmin, J P Morgan Chase, Gilead Sciences, Windstream, Cardinal Health, and QEP Resources — Research Highlights Growth, Revenue, and Consolidated Results |
| 10/26/2017 |
BW
| Gilead Sciences Announces Third Quarter 2017 Financial Results |
| 10/12/2017 |
BW
| Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017 |
| 09/05/2017 |
BW
| Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Monday, September 11 |
| 09/01/2017 |
BW
| Gilead Sciences to Present at Citi's 12th Annual Biotech Conference on Wednesday, September 6 |
| 07/26/2017 |
BW
| Gilead Sciences Announces Second Quarter 2017 Financial Results |
| 07/12/2017 |
BW
| Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017 |
| 06/01/2017 |
BW
| Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15 |
| 05/30/2017 |
BW
| Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13 |
| 05/02/2017 |
BW
| Gilead Sciences Announces First Quarter 2017 Financial Results |
| 04/18/2017 |
BW
| Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017 |
| 02/08/2017 |
BW
| Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22 |
| 02/07/2017 |
BW
| Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results |
| 08/15/2011 |
BW
| Gilead's Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective in Pivotal Phase 3 Clinical Study 102 |
| 07/20/2011 |
BW
| Gilead's Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks |
| 07/19/2011 |
BW
| Gilead Sciences to Release Second Quarter 2011 Financial Results on Tuesday, July 26, 2011 |
| 07/12/2011 |
BW
| Gilead Expands Access Program for Medications in Developing World |
| 06/28/2011 |
BW
| Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista® |
| 06/08/2011 |
BW
| Gilead Sciences to Present at the 31st Annual William Blair & Company Growth Stock Conference on Wednesday, June 15 |
| 05/31/2011 |
BW
| Gilead Sciences to Present at Two Upcoming Investor Conferences |
|